Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LPAR5 encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. Additionally we are shipping Lysophosphatidic Acid Receptor 5 Proteins (5) and many more products for this protein.
Showing 10 out of 44 products:
Human Polyclonal LPAR5 Primary Antibody for IHC (p) - ABIN4331424
Dottori, Leung, Turnley, Pébay: Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells. in Stem cells (Dayton, Ohio) 2008
These results suggest that the cell motile activity is regulated through the induction of LPA5 by phorbol ester and anticancer drug treatments in A375cells.
These results suggest that the diverse roles of LPA4 (show LPAR4 Antibodies), LPA5 and LPA6 (show LPAR6 Antibodies) are involved in the activation of tumor progression in pancreatic cancer cells.
Down-regulation of LPA receptor 5 contributes to aberrant LPA (show APOA Antibodies) signalling in EBV-associated nasopharyngeal carcinoma.
MMP-2 (show MMP2 Antibodies) and MMP-9 (show MMP9 Antibodies) were found in HT1080L5 cells, in comparison with control cells. These results suggest that LPA (show APOA Antibodies) signaling via LPA5 negatively regulates the cell motile and invasive activities of human sarcoma cells.
These results suggest that LPA5 may act as a negative regulator of cellular responses in mouse fibroblast 3T3 cells, similar to the case for LPA1 (show LPAR1 Antibodies).
It was shown that lysophosphatidic acid 5 receptor transactivated the epidermal growth factor receptor (show EGFR Antibodies) and that inhibition of epidermal growth factor receptor (show EGFR Antibodies) blocked lysophosphatidic acid 5 receptor-dependent activation of NHE3 (show SLC9A3 Antibodies).
LPA5 is a bona fide LPA (show APOA Antibodies) receptor on human mast cells responsible for the majority of LPA (show APOA Antibodies) induced MIP-1beta (show CCL4 Antibodies) release.
LPA4 (show LPAR4 Antibodies) and LPA5 receptors induce osteoblastic differentiation of human mesenchymal stem cells
Data show that CLL cells express LPA (show APOA Antibodies) receptors LPA(1 (show LPAR1 Antibodies)-5) and VEGF (show VEGFA Antibodies) receptors, and the plasma levels of VEGF (show VEGFA Antibodies) are elevated in CLL patients.
GPR92 is proposed as a fifth LPA (show APOA Antibodies) receptor, LPA5, which likely has distinct physiological functions in view of its expression pattern.
Findings suggest that lysophosphatidic acid receptor 5 antagonists elicit broad analgesic effects against both neuropathic and inflammatory pain.
These findings suggest that tumor and stromal LPA (show LPA Antibodies) receptors, in particular LPA1 (show LPAR1 Antibodies) and LPA5, play different roles in invasion and the seeding of metastasis
Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response
These data expand the influences of LPA (show LPA Antibodies) signaling in neuropathic pain through a second LPA (show LPA Antibodies) receptor subtype, LPA(5), involving a mechanistically distinct downstream signaling pathway compared with LPA(1 (show LPAR1 Antibodies)).
Lysophosphatidic acid (LPA (show LPA Antibodies)) is a potent stimulant of NHE3 (show SLC9A3 Antibodies) and fluid absorption in the intestine, signaling through LPA(5). Regulation by LPA(5) depends on its interaction with NHERF2 (show SLC9A3R2 Antibodies).
GPR92 is highly expressed in the lymphocyte compartment of the gastrointestinal tract
Our data indicate that GPR93 can contribute to the observed induction of CCK expression and secretion by peptone and provide evidence that G protein-coupled receptors can transduce dietary luminal signals.
This gene encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. This protein transmits extracellular signals from lysophosphatidic acid to cells through heterotrimeric G proteins and mediates numerous cellular processes. Many G protein receptors serve as targets for pharmaceutical drugs. Transcript variants of this gene have been described.
G protein-coupled receptor 92
, G-protein coupled receptor 92
, G-protein coupled receptor 93
, LPA receptor 5
, lysophosphatidic acid receptor 5
, putative G protein-coupled receptor 92
, lysophosphatidic acid receptor 5a
, lysophosphatidic acid receptor 6 like
, purinergic receptor P2Y, G-protein coupled, 5